Granted Patent
B2
US 12,497,442 · App. 18/739,702 · Granted Dec 16, 2025
Nucleic acids encoding modified immunoglobulin Fc regions
Assignee:
MABSOLVE LIMITED
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided are proteins comprising a variant IgG Fc region, wherein the proteins exhibit significantly reduced binding to human FcγRI when compared with a reference protein comprising the amino acid substitutions L234A/L235A/P329G. Also provided are compositions, methods of treatment and methods to reduce Fc-induced effector functions in a parent protein.
Claims (21)
1 . A nucleic acid comprising a nucleotide sequence encoding a protein comprising a variant IgG Fc region or a variant Cγ2 domain, wherein the variant IgG Fc region or variant Cγ2 domain is either:
(i) a variant Fc region or variant Cγ2 domain which comprises a combination of amino acids selected from the group consisting of: 234A/235T/236R, 234D/235H/236R, 234D/235K/236R, 234D/235Q/236R, 234D/235S/236R, 234D/235T/236R, 234E/235D/236R, 234E/235H/236R, 234E/235I/236R, 234E/235V/236R, 234G/235Q/236R, 234G/235S/236R, 234H/235I/236R, 234H/235S/236R, 234K/235Q/236R, 234K/235R/236R, 234K/235S/236R, 234K/235T/236R, 234K/235V/236R, 234Q/235A/236R, 234Q/235D/236R, 234Q/235H/236R, 234Q/235Q/236R, 234Q/235R/236R, 234Q/235S/236R, 234Q/235T/236R, 234Q/235V/236R, 234R/235D/236R, 234R/235E/236R, 234R/235H/236R, 234R/235I/236R, 234R/235K/236R, 234R/235Q/236R, 234R/235R/236R, 234R/235T/236R, 234S/235D/236R, 234S/235E/236R, 234S/235G/236R, 234S/235H/236R, 234S/23511236R, 234S/235R/236R, 234S/235T/236R, 234S/235V/236R, 234T/235A/236R, 234T/235I/236R, 234T/235K/236R, 234T/235Q/236R, 234T/235R/236R, 234T/235S/236R, 234T/235T/236R, and 234T/235V/236R;
(ii) a variant human IgG2 Fc region or variant IgG2 Cγ2 domain which comprises a combination of amino acids selected from: 234A/235T/236R, 234D/235H/236R, 234D/235K/236R, 234D/235Q/236R, 234D/235S/236R, 234D/235T/236R, 234E/235D/236R, 234E/235H/236R, 234E/235I/236R, 234E/235V/236R, 234G/235Q/236R, 234G/235S/236R, 234H/235I/236R, 234H/235S/236R, 234K/235Q/236R, 234K/235R/236R, 234K/235S/236R, 234K/235T/236R, 234K/235V/236R, 234Q/235D/236R, 234Q/235H/236R, 234Q/235Q/236R, 234Q/235R/236R, 234Q/235S/236R, 234Q/235T/236R, 234Q/235V/236R, 234R/235D/236R, 234R/235E/236R, 234R/235H/236R, 234R/235I/236R, 234R/235K/236R, 234R/235L/236R, 234R/235Q/236R, 234R/235R/236R, 234R/235T/236R, 234S/235D/236R, 234S/235E/236R, 234S/235G/236R, 234S/235H/236R, 234S/235I/236R, 234S/235L/236R, 234S/235R/236R, 234S/235T/236R, 234S/235V/236R, 234T/235I/236R, 234T/235K/236R, 234T/235Q/236R, 234T/235R/236R, 234T/235S/236R, 234T/235T/236R, and 234T/235V/236R; or
(iii) a variant human IgG4 Fc region or variant IgG4 Cγ2 domain which comprises a combination of amino acids selected from: 234A/235T/236R, 234D/235H/236R, 234D/235K/236R, 234D/235Q/236R, 234D/235S/236R, 234D/235T/236R, 234E/235D/236R, 234E/235H/236R, 234E/235I/236R, 234E/235V/236R, 234G/235Q/236R, 234G/235S/236R, 234H/235I/236R, 234H/235S/236R, 234K/235Q/236R, 234K/235R/236R, 234K/235S/236R, 234K/235T/236R, 234K/235V/236R, 234Q/235A/236R, 234Q/235D/236R, 234Q/235H/236R, 234Q/235Q/236R, 234Q/235R/236R, 234Q/235S/236R, 234Q/235T/236R, 234Q/235V/236R, 234R/235D/236R, 234R/235E/236R, 234R/235H/236R, 234R/235I/236R, 234R/235K/236R, 234R/235Q/236R, 234R/235R/236R, 234R/235T/236R, 234S/235D/236R, 234S/235E/236R, 234S/235G/236R, 234S/235H/236R, 234S/235I/236R, 234S/235R/236R, 234S/235T/236R, 234S/235V/236R, 234T/235A/236R, 234T/235I/236R, 234T/235K/236R, 234T/235Q/236R, 234T/235R/236R, 234T/235S/236R, 234T/235T/236R, and 234T/235V/236R;
wherein the amino acid numbering for (i), (ii) and (iii) is according to the EU index as in Kabat, and
wherein the binding of the protein to human FcγRI, when measured by surface plasmon resonance, is less than 50% of the binding of a reference protein comprising an Fc region comprising the amino acid sequence of SEQ ID NO: 2.
2 . A composition comprising the nucleic acid of claim 1 .
3 . A vector comprising the nucleic acid of claim 1 .
4 . A host cell comprising the nucleic acid of claim 1 .
5 . A method of making a protein, the method comprising, culturing the host cell of claim 4 and isolating the protein encoded thereby.
6 . A method to reduce Fc-mediated binding or Fc-mediated effector function of a protein comprising an IgG Fc region or a Cγ2 domain, the method comprising:
(i) design, synthesis, and expression of the nucleic acid of claim 1 ; and
(ii) isolation of the protein encoded by the nucleic acid of claim 1 .
7 . The nucleic acid of claim 1 , wherein the variant Fc region or variant Cγ2 domain comprises a combination of amino acids selected from the group consisting of 234G/235S/236R, 234S/235T/236R, 234S/235V/236R, 234T/235Q/236R, and 234T/235T/236R, and wherein the amino acid numbering is according to the EU index as in Kabat.
8 . A composition comprising the nucleic acid of claim 7 .
9 . A vector comprising the nucleic acid of claim 7 .
10 . A host cell comprising the nucleic acid of claim 7 .
11 . A method of making a protein, the method comprising culturing the host cell of claim 10 and isolating the protein encoded thereby.
12 . A method to reduce Fc-mediated binding or Fc-mediated effector function of a protein comprising an IgG Fc region or a Cγ2 domain, the method comprising:
(i) design, synthesis and expression of the nucleic acid of claim 7 ; and
(ii) isolation of the protein encoded by the nucleic acid of claim 7 .
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 17, 2024
From: HALE, GEOFFREY; WILKINSON, IAN
To: MABSOLVE LIMITED
Reel/Frame 067743/0737 →
Priority Claims (1)
GB 2007613
· May 21, 2020
· national
Continuity (3)
Continuation
PCTGB2021051233
· May 20, 2021
References Cited (211)
US 5648260A
· Winter et al.
· 1997
[cited by applicant]
US 6194551B1
· Idusogie et al.
· 2001
[cited by applicant]
US 6737056B1
· Presta
· 2004
[cited by applicant]
US 7597889B1
· Armour et al.
· 2009
[cited by applicant]
US 7662925B2
· Lazar et al.
· 2010
[cited by applicant]
US 7960512B2
· Stavenhagen et al.
· 2011
[cited by applicant]
US 8399618B2
· Lazar et al.
· 2013
[cited by applicant]
US 8409568B2
· Gao et al.
· 2013
[cited by applicant]
US 8871204B2
· Brezski et al.
· 2014
[cited by applicant]
US 8883147B2
· Lazar et al.
· 2014
[cited by applicant]
US 8961967B2
· Strohl et al.
· 2015
[cited by applicant]
US 8969526B2
· Baehner et al.
· 2015
[cited by applicant]
US 9040041B2
· Desjarlais et al.
· 2015
[cited by applicant]
US 9718893B2
· Jung et al.
· 2017
[cited by applicant]
US 9771426B2
· Georgiou et al.
· 2017
[cited by applicant]
US 9969800B2
· Igawa et al.
· 2018
[cited by applicant]
US 20060235208A1
· Lazar et al.
· 2006
[cited by applicant]
US 20070041966A1
· Armour et al.
· 2007
[cited by applicant]
US 20070219133A1
· Lazar et al.
· 2007
[cited by applicant]
US 20090060906A1
· Barry et al.
· 2009
[cited by applicant]
US 20110059078A1
· Coyle et al.
· 2011
[cited by applicant]
US 20150071948A1
· Lazar et al.
· 2015
[cited by applicant]
US 20190100587A1
· Brack et al.
· 2019
[cited by applicant]
EP 0307434A1
· 1989
[cited by applicant]
EP 1423431A2
· 2004
[cited by applicant]
EP 1873166A1
· 2008
[cited by applicant]
EP 1931709A2
· 2008
[cited by applicant]
EP 2486141A1
· 2012
[cited by applicant]
EP 2647707A1
· 2013
[cited by applicant]
EP 2691417A1
· 2014
[cited by applicant]
EP 2794658A1
· 2014
[cited by applicant]
WO WO1988007089A1
· 1988
[cited by applicant]
WO WO1994028027A1
· 1994
[cited by applicant]
WO WO1999058572A1
· 1999
[cited by applicant]
WO WO2000042072A2
· 2000
[cited by applicant]
WO WO2006033386A1
· 2006
[cited by applicant]
WO WO2006047350A2
· 2006
[cited by applicant]
WO WO2006053301A2
· 2006
[cited by applicant]
WO WO2006076594A2
· 2006
[cited by applicant]
WO WO2006105338A2
· 2006
[cited by applicant]
WO WO2008092117A2
· 2008
[cited by applicant]
WO WO2008145142A1
· 2008
[cited by applicant]
WO WO2009100309A2
· 2009
[cited by applicant]
WO WO2010063785A2
· 2010
[cited by applicant]
WO WO2011066501A1
· 2011
[cited by applicant]
WO WO2012022982A2
· 2012
[cited by applicant]
WO WO2012130831A1
· 2012
[cited by applicant]
WO WO2012168199A1
· 2012
[cited by applicant]
WO WO2013165690A1
· 2013
[cited by applicant]
WO WO2013186719A1
· 2013
[cited by applicant]
WO WO2014020056A1
· 2014
[cited by applicant]
WO WO2014108483A1
· 2014
[cited by applicant]
WO WO2016207858A1
· 2016
[cited by applicant]
WO WO2017019565A2
· 2017
[cited by applicant]
WO WO2017040380A2
· 2017
[cited by applicant]
WO WO2017046994A1
· 2017
[cited by applicant]
WO WO2017079369A2
· 2017
[cited by applicant]
WO WO2018044948A1
· 2018
[cited by applicant]
WO WO2018089300A1
· 2018
[cited by applicant]
WO WO2018187799A1
· 2018
[cited by applicant]
WO WO2018200422A1
· 2018
[cited by applicant]
WO WO2019211472A1
· 2019
[cited by applicant]
WO WO2020052692A2
· 2020
[cited by applicant]
WO WO2020086776A1
· 2020
[cited by applicant]
WO PCTGB2021051233
· 2021
[cited by applicant]
WO WO2021176424A1
· 2021
[cited by applicant]
Chapel et al, 1993. Journal of Biological Chemistry. 268(33): 25124-25131.
[cited by examiner]
Alegre et al., “Effect of a single amino acid mutation on the activating and immunosuppressive properties of a “humanized” OKT3 monoclonal antibody,” J Immunol. 1992; 148(11):3461-8.
[cited by applicant]
Angal et al., “A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (lgG4) antibody,” Mol Immunol. Jan. 1993;30(1):105-8.
[cited by applicant]
Armour et al., “Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities,” Eur J Immunol. Aug. 1999;29(8):2613-24.
[cited by applicant]
Bajaj et al., “Stability Testing of Pharmaceutical Products,” J Appl Pharm Sci. Mar. 2012;2(3):129-38.
[cited by applicant]
Beck and Reichert, “Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies,” MAbs. Sep.-Oct. 2011;3(5):415-6.
[cited by applicant]
Boesch et al., “Highly parallel characterization of IgG Fc binding interactions,” MAbs. Jul.-Aug. 2014;6(4):915-27.
[cited by applicant]
Bolt et al., “The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties,” Eur J Immunol. Feb. 1993;23(2):403-11.
[cited by applicant]
Borrok et al., “An “Fc-Silenced” IgG1 Format With Extended Half-Life Designed for Improved Stability,” J Pharm Sci. Apr. 2017;106(4):1008-1017.
[cited by applicant]
Brinkmann and Kontermann, “The making of bispecific antibodies,” MAbs. Feb./Mar. 2017;9(2): 182-212.
[cited by applicant]
Brinks et al., “Preclinical models used for immunogenicity prediction of therapeutic proteins,” Pharm Res. Jul. 2013;30(7):1719-28.
[cited by applicant]
Bruhns et al., “Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses,” Blood. Apr. 16, 2009;113(16):3716-25.
[cited by applicant]
Bryson et al., “Prediction of immunogenicity of therapeutic proteins: validity of computational tools,” BioDrugs. Feb. 1, 2010;24(1):1-8.
[cited by applicant]
Chen et al., “Immunogenicity of the outer domain of a HIV-1 clade C gp120,” Retrovirology. May 17, 2007;4:33.
[cited by applicant]
Choi et al., “A heterodimeric Fc-based bispecific antibody simultaneously targeting VEGFR-2 and Met exhibits potent antitumor activity,” Mol Cancer Ther. Dec. 2013;12(12):2748-59.
[cited by applicant]
Choi et al., “Crystal structures of immunoglobulin Fc heterodimers reveal the molecular basis for heterodimer formation,” Mol Immunol. Jun. 2015;65(2):377-83.
[cited by applicant]
Choi et al., “Engineering of Immunoglobulin Fc Heterodimers Using Yeast Surface-Displayed Combinatorial Fc Library Screening,” PLoS One. Dec. 16, 2015;10(12):e0145349.
[cited by applicant]
Combined Search and Examination Report from GB2007613.9 dated Jan. 13, 2021.
[cited by applicant]
Costa et al., “Glycosylation: impact, control and improvement during therapeutic protein production,” Crit Rev Biotechnol. Dec. 2014;34(4):281-99.
[cited by applicant]
Dall'Acqua et al., “Modulation of the effector functions of a human IgG1 through engineering of its hinge region,” J Immunol. Jul. 15, 2006;177(2):1129-38.
[cited by applicant]
Datta-Mannan and Wroblewski, “Application of FcRn binding assays to guide mAb development,” Drug Metab Dispos. Nov. 2014;42(11):1867-72.
[cited by applicant]
De Jong et al., “A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface,” PLoS Biol. Jan. 6, 2016;14(1):e1002344.
[cited by applicant]
De Nardis et al., “A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G1,” J Biol Chem. Sep. 1, 2017;292(35):14706-14717.
[cited by applicant]
Den Engelsman et al., “Strategies for the assessment of protein aggregates in pharmaceutical biotech product development,” Pharm Res. Apr. 2011;28(4):920-33.
[cited by applicant]
Deng et al., “Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys,” Drug Metab Dispos. Apr. 2010;38(4):600-5.
[cited by applicant]
Dhanda et al., “IEDB-AR: immune epitope database-analysis resource in 2019,” Nucleic Acids Res. Jul. 2, 2019;47(W1):W502-W506.
[cited by applicant]
Dumet et al., “Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development,” MAbs. 2019;11(8):1341-1350.
[cited by applicant]
Edelman et al., “The covalent structure of an entire gammaG immunoglobulin molecule,” Proc Natl Acad Sci U S A. May 1969;63(1):78-85.
[cited by applicant]
Examination Report from CA3179582 dated Feb. 10, 2023.
[cited by applicant]
Fan et al., “A novel therapeutic strategy to rescue the immune effector function of proteolytically inactivated cancer therapeutic antibodies,” Mol Cancer Ther. Mar. 2015;14(3):681-91.
[cited by applicant]
Finco et al., “Cytokine release assays: current practices and future directions,” Cytokine. Apr. 2014;66(2):143-55.
[cited by applicant]
Findlay et al., “Endothelial cells co-stimulate peripheral blood mononuclear cell responses to monoclonal antibody TGN1412 in culture,” Cytokine. Jul. 2011;55(1):141-51.
[cited by applicant]
Findlay et al., “Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412,” J Immunol Methods. Jan. 31, 2010;352(1-2):1-12.
[cited by applicant]
First Examination Report from AU 2021277578 dated Dec. 22, 2022.
[cited by applicant]
Fleri et al., “The Immune Epitope Database and Analysis Resource in Epitope Discovery and Synthetic Vaccine Design,” Front Immunol. Mar. 14, 2017;8:278.
[cited by applicant]
Greenbaum et al., “Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes,” Immunogenetics. Jun. …
[cited by applicant]
Greenwood et al., “Structural motifs involved in human IgG antibody effector functions,” Eur J Immunol. 1993;23(5):1098-104.
[cited by applicant]
Gregorio et al., “A User's Guide to Cell-Free Protein Synthesis,” Methods Protoc. Mar. 12, 2019;2(1):24.
[cited by applicant]
Grimaldi et al., “Cytokine release: A workshop proceedings on the state-of-the-science, current challenges and future directions,” Cytokine. Sep. 2016;85:101-8.
[cited by applicant]
Gunasekaran et al., “Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG,” J Biol Chem. Jun. 18, 2010;285(25):19637-46.
[cited by applicant]
Hale et al., “Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement,” Blood. Oct. 1983;62(4):873-82.
[cited by applicant]
Hezareh et al., “Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1,” J Virol. Dec. 2001;75(24):12161-8.
[cited by applicant]
Hinton et al., “Engineered human IgG antibodies with longer serum half-lives in primates,” J Biol Chem. Feb. 20, 2004;279(8):6213-6.
[cited by applicant]
Horton et al., “Antibody-mediated coengagement of Fc?RIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus,” J Immunol. Apr. 1, 2011;186(7):4223-33.
[cited by applicant]
Horton et al., “Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia,” Cancer Res. 2008;68(19):8049-57.
[cited by applicant]
Hsiao et al., “Proteolytic single hinge cleavage of pertuzumab impairs its Fc effector function and antitumor activity in vitro and in vivo,” Breast Cancer Res. 2018;20(43).
[cited by applicant]
Idusogie et al., “Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc,” J Immunol. Apr. 15, 2000;164(8):4178-84.
[cited by applicant]
International Preliminary Report on Patenability from PCT/GB/2021/051233 dated Aug. 24, 2022.
[cited by applicant]
Ishino et al., “Engineering a monomeric Fc domain modality by N-glycosylation for the half-life extension of biotherapeutics,” J Biol Chem. Jun. 7, 2013;288(23):16529-16537.
[cited by applicant]
Jafari et al., “Fc-fusion Proteins in Therapy: An Updated View,” Curr Med Chem. 2017;24(12):1228-1237.
[cited by applicant]
Jain, et al. “Biophysical properties of the clinical-stage antibody landscape.” Proc Natl Acad Sci U S A. Jan. 31, 2017;114(5):944-949. doi: 10.1073/pnas.1616408114. Epub Jan. 17, 2017. PMID: 28096333; Pmcid: PMC5293111.
[cited by applicant]
Jawa et al., “T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation,” Clin Immunol. Dec. 2013;149(3):534-55.
[cited by applicant]
Jefferis, “Glycosylation of recombinant antibody therapeutics,” Biotechnol Prog. Jan.-Feb. 2005;21(1):11-6.
[cited by applicant]
Jensen et al., “Improved methods for predicting peptide binding affinity to MHC class II molecules,” Immunology. Jul. 2018;154(3):394-406.
[cited by applicant]
Joubert et al., “Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics,” PLoS One. Aug. 5, 2016;11(8):e0159328.
[cited by applicant]
Kanda et al., “Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types,” Glycobiology. Jan. 2007;…
[cited by applicant]
Kim et al., “Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn,” Eur J Immunol. Sep. 1999;29(9):2819-25.
[cited by applicant]
King et al., “Removing T-cell epitopes with computational protein design,” Proc Natl Acad Sci U S A. Jun. 10, 2014;111(23):8577-82.
[cited by applicant]
Kuo and Aveson, “Neonatal Fc receptor and IgG-based therapeutics,” MAbs. Sep.-Oct. 2011;3(5):422-30.
[cited by applicant]
Labrijn et al., “Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange,” Proc Natl Acad Sci U S A. Mar. 26, 2013;110(13):5145-50.
[cited by applicant]
Lazar et al., “Engineered antibody Fc variants with enhanced effector function,” Proc Natl Acad Sci U S A. Mar. 14, 2006;103(11):4005-10.
[cited by applicant]
Leaver-Fay et al., “Computationally Designed Bispecific Antibodies using Negative State Repertoires,” Structure. Apr. 5, 2016;24(4):641-651.
[cited by applicant]
Lee et al., “An engineered human Fc domain that behaves like a pH-toggle switch for ultra-long circulation persistence,” Nat Commun. Nov. 6, 2019;10(1):5031.
[cited by applicant]
Lin et al., “The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity,” Cancer Biol Ther. Nov. 2013;1…
[cited by applicant]
Liu, “Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins,” Protein Cell. Jan. 2018;9(1):15-32.
[cited by applicant]
Loureiro et al., “Adjuvant-Free Immunization with Hemagglutinin-Fc Fusion Proteins as an Approach to Influenza Vaccines,” J Virol. Mar. 2011;85(6):3010-4.
[cited by applicant]
Lund et al., “Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains,” J Immunol. Dec. 1…
[cited by applicant]
Lund et al., “Human Fc gamma RI and Fc gamma RII interact with distinct but overlapping sites on human lgG,” J Immunol. 1991;147(8):2657-62.
[cited by applicant]
Mekhaiel et al., “Polymeric human Fc-fusion proteins with modified effector functions,” Sci Rep. 2011;1:124.
[cited by applicant]
Merchant et al., “An efficient route to human bispecific IgG,” Nat Biotechnol. Jul. 1998; 16(7):677-81.
[cited by applicant]
Michaelson et al., “Structural difference in the complement activation site of human IgG1 and IgG3,” Scand J Immunol. Dec. 2009;70(6):553-64.
[cited by applicant]
Mimoto et al., “Engineering to Improve the Function of Therapeutic Antibodies,” Curr Pharm Biotechnol. 2016;17(15):1298-1314.
[cited by applicant]
Moore et al., “A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens,” MAbs. Nov.-Dec. 2011;3(6):546-57.
[cited by applicant]
Moore et al., “A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats,” Methods. Feb. 1, 2019;154:38-50.
[cited by applicant]
Moore et al., “Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions,” MAbs. Mar.-Apr. 2010;2(2):181-9.
[cited by applicant]
Morgan et al., “The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding,” Immunology. 1995;86(2):319-24.
[cited by applicant]
Neville et al., “Analysis of fluorescently labeled glycosphingolipid-derived oligosaccharides following ceramide glycanase digestion and anthranilic acid labeling,” Anal Biochem. Aug. 15, 2004;331(2):275-82.
[cited by applicant]
Nielson et al., “Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method,” BMC Bioinformatics. Jul. 4, 2007;8:238.
[cited by applicant]
Niesen et al., “The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability,” Nat Protoc. 2007;2(9):2212-21.
[cited by applicant]
Niles et al., “A homogeneous assay to measure live and dead cells in the same sample by detecting different protease markers,” Anal Biochem. Jul. 15, 2007;366(2):197-206.
[cited by applicant]
Oganesyan et al., “Structural characterization of a human Fc fragment engineered for lack of effector functions,” Acta Crystallogr D Biol Crystallogr. Jun. 2008;64(Pt 6):700-4.
[cited by applicant]
Partial Search Report from PCT/GB/2021/051233 dated May 20, 2021.
[cited by applicant]
Paul et al., “Development and validation of a broad scheme for prediction of HLA class II restricted T cell epitopes,” J Immunol Methods. Jul. 2015;422:28-34.
[cited by applicant]
PCT International Search Report and Written Option from PCT/GB/2021/051233, dated Nov. 25, 2021.
[cited by applicant]
Petkova et al., “Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease,” Int Immunol. Dec. 2006;18(12):1759-69.
[cited by applicant]
Proetzel and Roopenian, “Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies,” Methods. Jan. 1, 2014;65(1):148-53.
[cited by applicant]
Ramadhany et al., “Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection,” Antiviral Res. 2015;124(39):61-68.
[cited by applicant]
Reddy et al., “Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4,” J Immunol. 2000;164(4):1925-33.
[cited by applicant]
Reusch et al., “Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles—part 1: separation-based methods,” MAbs. 2015;7(1):167-79.
[cited by applicant]
Reusch et al., “Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles—Part 2: Mass spectrometric methods,” MAbs. 2015;7(4):732-42.
[cited by applicant]
Ridgway et al., “Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization,” Protein Eng. Jul. 1996;9(7):617-21.
[cited by applicant]
Rose et al., “Quantitative analysis of the interaction strength and dynamics of human IgG4 half molecules by native mass spectrometry,” Structure. Sep. 7, 2011;19(9):1274-82.
[cited by applicant]
Römer et al., “Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412,” Blood. Dec. 22, 2011;118(26):6772-82.
[cited by applicant]
Saunders, “Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life,” Front Immunol. 2019;10:1296.
[cited by applicant]
Schlothauer et al., “Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions,” 2016;29(10):457-466.
[cited by applicant]
Search Report from GB2007613.9 dated Jan. 8, 2021.
[cited by applicant]
Second Examination Report from GB2007613.9 dated Aug. 24, 2021.
[cited by applicant]
Second Office Action from CA 3, 179,582 dated Jun. 12, 2023.
[cited by applicant]
Senisterra and Finerty, “High throughput methods of assessing protein stability and aggregation,” Mol Biosyst. Mar. 2009;5(3):217-23.
[cited by applicant]
Shan et al., “Generation and Characterization of an IgG4 Monomeric Fc Platform,” PLoS One. 2016;11(8):e0160345.
[cited by applicant]
Shields et al., “High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R,” J Biol Chem. Mar. 2…
[cited by applicant]
Shire, “Formulation and manufacturability of biologics,” Curr Opin Biotechnol. 2009;20(6):708-14.
[cited by applicant]
Sidney et al., “Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries,” Immunome Res. Jan. 25, 2008;4:2.
[cited by applicant]
Simeon and Chen, “In vitro-engineered non-antibody protein therapeutics,” Protein Cell. Jan. 2018;9(1):3-14.
[cited by applicant]
Stapleton et al., “Human IgG lacking effector functions demonstrate lower FcRn-binding and reduced transplacental transport,” Mol Immunol. Mar. 2018;95:1-9.
[cited by applicant]
Strohl, “Current progress in innovative engineered antibodies,” Protein Cell. 2018;9(1):86-120.
[cited by applicant]
Strop et al., “Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair,” J Mol Biol. 2012;420(3):204-19.
[cited by applicant]
Sturniolo et al., “Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices,” Nat Biotechnol. Jun. 1999;17(6):555-61.
[cited by applicant]
Tam et al., “Functional, Biophysical, and Structural Characterization of Human IgG1 and IgG4 Fc Variants with Ablated Immune Functionality,” Antibodies (Basel). Sep. 1, 2017;6(3):12.
[cited by applicant]
Third Examination Report from GB2007613.9 dated Dec. 15, 2021.
[cited by applicant]
Vaccaro et al., “Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels,” Nat Biotechnol. Oct. 2005;23(10):1283-8.
[cited by applicant]
Vafa et al., “An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations,” Methods. Jan. 1, 2014;65(1):114-26.
[cited by applicant]
Vessillier et al., “Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials—Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm,” J Immunol Methods. S…
[cited by applicant]
Vidarsson et al., “IgG subclasses and allotypes: from structure to effector functions,” Front Immunol. 2014;5:520.
[cited by applicant]
Von Kreudenstein et al., “Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design,” MAbs. Sep.-Oct. 2013;5(5):646-54.
[cited by applicant]
Wang et al., “ IgG Fc engineering to modulate antibody effector functions,” Protein Cell. 2018;9(1):63-73.
[cited by applicant]
Wang et al., “A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach,” PLoS Comput Biol. Apr. 4, 2008;4(4):e1000048.
[cited by applicant]
Werner et al., “Glycosylation of therapeutic proteins in different production systems,” Acta Paediatr. 2007;96(455):17-22.
[cited by applicant]
Wilkinson et al., “Monovalent IgG4 molecules: immunoglobulin Fc mutations that result in a monomeric structure,” MAbs. May-Jun. 2013;5(3):406-17.
[cited by applicant]
Wing et al., “Ex-vivo whole blood cultures for predicting cytokine-release syndrome: dependence on target antigen and antibody isotype,” Ther Immunol. Aug. 1995;2(4):183-90.
[cited by applicant]
Wolf et al., “A whole blood in vitro cytokine release assay with aqueous monoclonal antibody presentation for the prediction of therapeutic protein induced cytokine release syndrome in humans,” Cytokine. Dec. 2012;60(3)…
[cited by applicant]
Wozniak-Knopp et al., “Designing Fcabs: well-expressed and stable high affinity antigen-binding Fc fragments,” Protein Eng Des Sel. Sep. 1, 2017;30(9):657-671.
[cited by applicant]
Written Opinion of the International Preliminary Examining Authority from PCT/GB/2021/051233 dated Jul. 14, 2022.
[cited by applicant]
Written Opinion of the International Preliminary Examining Authority from PCT/GB/2021/051233 dated Mar. 31, 2022.
[cited by applicant]
Xu et al., “In vitro characterization of five humanized OKT3 effector function variant antibodies,” Cell Immunol. Feb. 25, 2000;200(1):16-26.
[cited by applicant]
Yang et al., “Engineering of Fc Fragments with Optimized Physicochemical Properties Implying Improvement of Clinical Potentials for Fc-Based Therapeutics,” Front Immunol. Jan. 8, 2018;8:1860.
[cited by applicant]
Yeung et al., “Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates,” J Immunol. Jun. 15, 2009;182(12):7663-71.
[cited by applicant]
Ying et al., “Monomeric IgG1 Fc molecules displaying unique Fc receptor interactions that are exploitable to treat inflammation-mediated diseases,” MAbs. 2014;6(5):1201-10.
[cited by applicant]
Ying et al., “Soluble monomeric IgG1 Fc,” J Biol Chem. Jun. 1, 2012;287(23):19399-408.
[cited by applicant]
Zalevsky et al., “Enhanced antibody half-life improves in vivo activity,” Nat Biotechnol. Feb. 2010;28(2):157-9.
[cited by applicant]
Zhou, “Site-Specific Antibody Conjugation for ADC and Beyond,” Biomedicines. Nov. 9, 2017;5(4):64.
[cited by applicant]
U.S. Appl. No. 18/057,420, filed Nov. 21, 2022, Geoffrey Hale.
[cited by applicant]
Final Rejection from KR 10-2022-704142, dated Jul. 25, 2025.
[cited by applicant]